Aplastic Anemia: Pathogenesis and Treatment | Zendy

Almalina Bacigalupo | Zendy; Giovanna Piaggio | Zendy; M. T. Van Lint | Zendy; O Figari | Zendy; A Marmont | Zendy; M. Congiu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aplastic Anemia: Pathogenesis and Treatment

Author(s) -

Almalina Bacigalupo,

Giovanna Piaggio,

M. T. Van Lint,

O Figari,

A Marmont,

M. Congiu

Publication year - 1987

Publication title -

oncology research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.553

H-Index - 48

eISSN - 2296-5262

pISSN - 2296-5270

DOI - 10.1159/000216399

Subject(s) - aplastic anemia , immunosuppression , pathogenesis , medicine , human leukocyte antigen , haematopoiesis , immunology , anemia , stem cell , bone marrow , biology , antigen , genetics

Treatment of severe aplastic anemia (SAA) in Europe between 1970 and 1986 is reviewed. 487 patients received an HLA-identical BMT: results are encouraging and currently suggest a 65% survival. However, many patients cannot be offered this procedure because of the absence of an appropriate donor. Forty-five patients were given a non-HLA identical BMT: results are dependent on the degree of mismatch. Immunosuppression (IS) was given to 509 patients: 50% of these survive. Some mechanisms regulating in vitro hematopoiesis are discussed, together with their relevance in the treatment of SAA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research